Most Read Articles
5 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.
Stephen Padilla, 6 days ago
A pharmacist intervention appears to be effective in lowering and preventing the incidence of prescribing errors of investigational drugs in oncology clinical trials, a recent study has shown.

Original New Drug Application Approvals by US FDA (16 - 30 June 2019)

02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

MYXREDLIN
  • Active Ingredient(s): Insulin human; sodium chloride
  • Strength:  100 mL; 9%
  • Dosage Form(s) / Route(s): Injectable; injection
  • Company: Celerity Pharms
  • Approval Date: 20 June 2019
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
  • Approved Label20 June 2019 (PDF)

VYLEESI
  • Active Ingredient(s): Bremelanotide acetate
  • Strength: 1.75 mg/0.3 mL
  • Dosage Form(s) / Route(s): Injectable; intravenous, subcutaneous
  • Company: Amag Pharms, Inc.
  • Approval Date: 21 June 2019
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
    • A co-existing medical or psychiatric condition,
    • Problems with the relationship, or
    • The effects of a medication or drug substance.
  • Approved Label21 June 2019 (PDF)

ZIRABEV
  • Active Ingredient(s): Bevacizumab-bvzr
  • Strength: 100 mg/4 mL; 400 mg/16 mL
  • Dosage Form(s) / Route(s): Injectable; injection
  • Company: Pfizer, Inc.
  • Approval Date: 27 June 2019
  • Submission Classification: Not available
  • Indication(s): Indicated for the treatment of:
    • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
    • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • Approved Label27 June 2019 (PDF)

THIOLA EC
  • Active Ingredient(s): Tiopronin
  • Strength: 100 mg; 300 mg
  • Dosage Form(s) / Route(s): Tablet, delayed release; oral
  • Company: Mission Pharmacal Co.
  • Approval Date: 28 June 2019
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Not available
  • Approved Label: Not available
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.
Stephen Padilla, 6 days ago
A pharmacist intervention appears to be effective in lowering and preventing the incidence of prescribing errors of investigational drugs in oncology clinical trials, a recent study has shown.